Close Menu

NEW YORK – Finnish diagnostics company Actim said on Tuesday it has received CE marking for the Actim ELISA SARS-CoV-2 IgG assay.

The test, which uses serum samples, provides semiquantitative detection of antibodies against SARS-CoV-2, allowing for the identification of patients who may have had the coronavirus. The assay has 96 percent sensitivity and 98 percent specificity, Actim said, adding it does not cross-react with IgG antibodies against other common viruses such as influenza A/B.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.